Iambic Therapeutics

Iambic Therapeutics is a disruptive force in the therapeutics landscape, pioneering a unique AI-driven drug-discovery platform. The company boasts a world-class team that combines leading AI experts and experienced drug hunters, known for successfully delivering clinically validated therapeutics. With a proven track record of delivering high-quality, differentiated therapeutics to the clinic at an unprecedented speed and across multiple target classes and mechanisms of action, Iambic is addressing urgent unmet patient needs with its internal pipeline of clinical assets. Founded in 2019 and headquartered in the United States, Iambic recently closed a $100.00M Series B investment on 03 October 2023, with participation from notable investors such as Illumina Ventures, Nvidia, OrbiMed, Catalio Capital Management, Gradiant, Ascenta Capital, Nexus Ventures, Bill Rastetter Rastetter, William Rastetter, and FreeFlow. For more information about Iambic's team, platform, and pipeline, visit iambic.ai.